ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2013
The impact of generic reference pricing in Italy, a decade on.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- The Impact of Tiered-Pricing Framework on Generic Entry in Canada.International journal of health policy and management · 2022Article
- Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science.Journal of pharmaceutical policy and practice · 2019Article
- Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study.Croatian medical journal · 2018Article
- Endogenous versus exogenous generic reference pricing for pharmaceuticals.International journal of health economics and management · 2017Article
- Unlocking the potential of established products: toward new incentives rewarding innovation in Europe.Journal of market access & health policy · 2017Article
- The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Article
- Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.International journal of health economics and management · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe generic reference price (GRP) was introduced in Italy in 2001. The main purpose of this paper is: (a) producing evidence regarding the effect of GRP on prices; (b) testing the hypothesis that there is a reallocation of demand from the genericated (and reference-priced) molecules to patent-protected products that have the same therapeutic indication.
methodsThe analysis used a unique dataset of quantities and revenues of six therapeutic groups that were observed for more than a decade. Difference-in-differences analysis is applied. Prices are adjusted for all the regulatory interventions in the ten years of observations, to control for confounding impact of these interventions.
resultsOn average, prices dropped 13% more in groups to which GRP was applied than in other groups. Moreover, each entry of a new generic was associated with a price drop of around 2.8%. On the other hand, GRP did not induce any significant switching towards in-patent molecules.
conclusionsWe provide the first empirical results of the impact of GRP on prices in Italy and evidence that GRP cannot be held solely responsible for the often reported demand reallocation towards new and in-patent molecules.
Indexed as
Identifiers
23183986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.